San Francisco — October 6, 2026. Multiply Labs, self-described as "the physical AI company" automating complex medicine-manufacturing processes with robotics, announced a $75 million Multiply Labs Series B, bringing its total capital raised to over $100 million since its 2016 founding.
The round was led by Dr. Patrick Soon-Shiong with NantWorks. New investors include AstraZeneca, Lingotto, Teradyne, and Strange Ventures, with returning participation from Casdin Capital, Lux Capital, Fifty Years, Ora Global, Founders Fund, among others.
The Thesis: Discovery Is Fast, Manufacturing Is Not
The investment case is a structural mismatch. Tens of billions of dollars are pouring into AI-driven drug discovery — but manufacturing timelines haven't kept up. Some biomanufacturing processes remain largely manual, and a single contamination event can cost millions of dollars and delay patient access to medicine.
Multiply Labs automates these processes with robotics, reducing contamination risk and increasing manufacturing capacity. The company positions itself as closing the gap between what AI can design and what patients can actually receive — a bottleneck that gets worse as AI-designed drugs arrive faster than factories can handle them.
Strategic Investors Signal Industry Validation
The investor roster reads like a conviction vote from the industry itself. AstraZeneca's participation as a new investor puts a major pharma directly behind the automation thesis, while Teradyne — a leader in industrial automation and robotics — brings deep manufacturing expertise to the cap table. The return of Founders Fund, Lux Capital, and Casdin Capital suggests the early thesis is tracking.
A Decade in the Making
Founded in 2016, Multiply Labs has been building toward this moment for a decade — long before "physical AI" became venture shorthand. Crossing $100 million in total funding marks the transition from R&D-heavy startup to a company scaling toward commercial manufacturing deployments.
The timing is not accidental. As AI drug-discovery platforms push more candidates into development pipelines, the manufacturing bottleneck grows tighter every year. Facilities running on manual processes cannot scale to meet the volume that modern discovery engines are capable of producing. Automation is the only way to keep the back end of drug development moving at the speed of the front end.
Multiply Labs' robotics-first approach also attacks one of pharma's most expensive failure modes: contamination. A single contamination event in a biologics facility can idle production lines for weeks, destroy batches worth millions, and — most importantly — delay treatments reaching patients. Reducing that risk is a proposition that sells itself to any manufacturing executive.
Why the Multiply Labs Series B Matters for Founders and Investors
For founders, this round validates one of the clearest remaining whitespace categories in biotech: the manufacturing layer beneath the AI drug-discovery boom. Every dollar flowing into AI-designed molecules increases the pressure on production infrastructure. Robotics, contamination control, and continuous manufacturing are all investable problems with pharma customers willing to pay.
For investors, the presence of AstraZeneca and Teradyne is the tell. When strategics lead or co-lead alongside top-tier venture firms, the exit paths multiply — literally. This is a company building the picks-and-shovels infrastructure for the next decade of medicine, and the capital markets are now pricing it accordingly.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



